WAYNE, Pa., Sept. 18, 2015 /PRNewswire/ -- Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of persons who purchased or acquired the shares of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company") (NASDAQ: NWBO) between March 8, 2013 and August 20, 2015, inclusive (the "Class Period").
Northwest Biotherapeutics shareholders may, no later than October 26, 2015, move the Court for appointment as a lead plaintiff of the Class. If you purchased shares of Northwest Biotherapeutics and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/nwbo.
The Complaint alleges that throughout the Class Period defendants concealed that: (1) claims regarding positive results from the DCVax-Direct Trial (the "Results") were based on preliminary and unconfirmed trial results; (2) the Results had not been reviewed or analyzed by the hospitals conducting the trials; (3) the Company's statements about the Results were derived from patient case report forms sent to the Company only because it sponsored the study; (4) the Company was the subject of an aggressive stock promotion campaign including promoters using false identities and credentials; (5) German regulators required additional information from the Company in order for the Company's DCVax-L Trial to continue uninterrupted; and (6) as a result of the above, the Company's financial statements were materially false and misleading.
SS&B is also investigating whether allegations in news reports that Northwest Biotherapeutics has used undisclosed, paid stock promoters to increase the value of its shares, which SS&B believes may have been a waste of corporate assets that exposed the Company to liability.
If you are a member of the class, you may, no later than October 26, 2015, request that the Court appoint you as lead plaintiff of the class. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide. To learn more about the class action process, please visit: www.rmclasslaw.com.
CONTACT: Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087
484-588-5516
877-316-3218
www.rmclasslaw.com/cases/nwbo
[email protected]
Logo - http://photos.prnewswire.com/prnh/20121112/MM11729LOGO
SOURCE Ryan & Maniskas, LLP
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article